<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694057</url>
  </required_header>
  <id_info>
    <org_study_id>HE3286-0401</org_study_id>
    <nct_id>NCT00694057</nct_id>
  </id_info>
  <brief_title>Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase II, Double Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerance and Activity of HE3286 When Administered Orally for 12 Weeks to Adult Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbor Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbor Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, double-blind, randomized, placebo-controlled study of the safety,
      tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients
      receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or
      placebo) for a treatment period of 12-weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hollis-Eden Pharmaceuticals, Inc. is developing a new class of therapeutics for the treatment
      of Type 2 diabetes. The investigational drug, HE3286, holds the potential to be the first in
      a new class of insulin sensitizers with a potentially novel mechanism of action that may
      improve the current therapeutic options available to a T2DM patient.

      This is a phase II, double-blind, randomized, placebo-controlled study of the safety,
      tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients
      receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or
      placebo) for a treatment period of 12-weeks. Changes in hemoglobin A1c (HbA1c) will be
      assessed over a treatment period of 12-weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the change in HbA1c from baseline to week 12 in the HE3286 treated group when compared to the placebo group.</measure>
    <time_frame>12-weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerance of HE3286 10 mg per day (5 mg BID) compared to placebo from baseline to week 12.</measure>
    <time_frame>12-weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of HE3286 on fasting blood glucose over time.</measure>
    <time_frame>12-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of HE3286 on insulin sensitivity over time.</measure>
    <time_frame>12-weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HE3286 10 mg (5 mg BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HE3286</intervention_name>
    <description>HE3286 10 mg per day (5 mg BID)</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patient with a diagnosis of Type 2 Diabetes Mellitus (T2DM)

          -  Patient must be a) on a stable dose of metformin as monotherapy for at least 10 weeks
             prior to screening; or b) drug-naive, defined as never having received drug treatment
             for T2DM or not having received antidiabetic drug therapy during the 3 months prior to
             screening.

          -  Patient with a fasting blood glucose level of ≤ 225 mg/dL at screening (≤ 255 mg/dl
             for drug-naive patients);

          -  Patient with HbA1c levels &gt;7.5% (7.0 - 10.5% for drug-naive patients) at screening;

          -  Patient with BMI 28-37 kg/m2 for females 28-39 kg/m2 for males

        Main Exclusion Criteria:

          -  Patient who has a history of clinically significant cardiovascular disease (including
             coronary artery disease), clinically significant hepatic, respiratory or renal
             abnormalities within 6 months prior to screening;

          -  Patient with unstable diabetic complications requiring treatment or ongoing active
             intervention;

          -  Patient with a history of long term insulin therapy within the past year;

          -  Patient who has had therapy with rosiglitazone, pioglitazone, exendin-4 or
             sitagliptin, alone or in combination within 6 months prior to screening;

          -  Patient who has any clinically significant abnormalities in laboratory results at
             screening;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dwight R. Stickney, MD</last_name>
    <role>Study Director</role>
    <affiliation>Harbor Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach,</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2008</study_first_posted>
  <last_update_submitted>June 11, 2011</last_update_submitted>
  <last_update_submitted_qc>June 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dwight Stickney, MD - Chief Medical Officer</name_title>
    <organization>Hollis-Eden Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Metformin</keyword>
  <keyword>HbA1c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

